In this podcast, we interviewed Dr. Paul Wotton, CEO, about Sigilon Therapeutics’ discovery platform. The platform combines cell engineering and biocompatible Afibromer™ technology to enable cell therapies that do not trigger fibrosis
View show notes at cellculturedish.com/novel-technology-enables-encapsulated-cell-therapeutics-without-triggering-fibrosis/
Podcast: Play in new window | Download | Embed
Subscribe: Apple Podcasts | Google Podcasts | Spotify | Stitcher | TuneIn | RSS | More